Table 3. Compounds or interventions investigated in registered pediatric phase 3 epilepsy clinical trials.
| Compound/Intervention | Published trials (N) | Unpublished trials (N) |
|---|---|---|
| Brivaracetam | 3 | 5* |
| Carbamazepine | 2 | 0 |
| Carisbamate | 3 | 3 |
| Clobazam | 2 | 0 |
| Diagnostic procedure (MEG vs. PET vs. MRI) | 0 | 1 |
| Diazepam | 2 | 0 |
| Eslicarbazepine | 0 | 2 |
| Fosphenytoin | 0 | 1 |
| Gabapentin | 2 | 0 |
| Lacosamide | 9 | 3** |
| Lamotrigine | 9 | 0 |
| Levetiracetam | 17 | 6* |
| Lorazepam | 4 | 0 |
| Melatonin | 0 | 1 |
| Midazolam | 1 | 0 |
| Modified Atkins diet | 2 | 0 |
| Natural progesterone | 1 | 0 |
| Oxcarbazepine | 2 | 2* |
| Paraldehyd | 1 | 0 |
| Perampanel | 3 | 0 |
| Phenytoin | 1 | 1 |
| Prednisolone | 1 | 0 |
| Pregabalin | 3 | 0 |
| Procedure (surgery) | 1 | 0 |
| Rufinamide | 3 | 1 |
| Topiramate | 7 | 5 |
| Valproate | 2 | 1 |
| Zonisamide | 4 | 1 |
Ten studies investigated multiple compounds.
*One trial or **two trials were completed in 2014.
MEG = magnetoencephalography, PET = positron emission tomography, MRI = magnetic resonance imaging